Neurology

Migraine is a chronic neurological disease characterized by throbbing or pulsating unilateral or bilateral headache that can last from hours to days.

The authors note this is the first study to assess cerebrovascular endothelial extracellular vesicles within a cognitive condition.

The chief product and strategy officer at Linus Health is hopeful that pharmacists can be key players in the detection of mild cognitive impairment.

The rare disease can result in progressive neurological symptoms and organ complications.

Tocilizumab reduced relapses in 4 patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD).

The FDA assigned a Prescription Drug User Fee Action date is January 31, 2025.

ALZ-801 has now progressed to the phase 3 APOLLOE4 study, designed to evaluate efficacy, safety, and biomarker and imaging effects.

In a promising development in multiple sclerosis research, tolebrutinib delayed the onset of disability progression in patients with nrSPMS.

The hospital pharmacists’ role in treating patients with epilepsy starts with their place on the multidisciplinary team, which identifies appropriate drug selection in the hospital. It continues with counseling and therapy reconciliation to assure smooth transitions upon patient discharge to the community.

Despite questions and controversy around some clinical research, new understandings of the pathophysiology of the disease are pushing treatments forward.

Mirdametinib is an oral, allosteric small molecule MEK inhibitor to treat pediatric patients with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN).

Community pharmacists can participate in continuing education epilepsy programs, but they are usually not specific to pharmacy practice.

The Alzheimer disease treatment landscape is evolving with new FDA-approved antibody therapies and advancements in biomarker testing to enable earlier diagnosis and intervention.

Findings from 2 large datasets suggest hormone therapy may reduce Alzheimer risk, hippocampal atrophy, and cerebrovascular disease.

Carbidopa and levodopa extended-release capsules are a novel, oral formulation that combine immediate-release granules and extended-release pellets.

Improvements were observed in both the intervention and control group, with those who had self-reported learning difficulties showing the least improvement.

Small adjustments in human pluripotent stem cell cultures and the molecule concentration patterns in the initial 5 days of differentiation are essential to “rescue” the lines.

Periodontitis and AD are both characterized by inflammatory and immunological response by the host.

In addition to a rapid deterioration, psychosis in Alzheimer disease can also lead to poorer quality of life, damaged patient-caregiver relationships, and increased isolation.

The findings show that inhibiting connexin 43 significantly improves multiple sclerosis symptoms in an experimental mouse model.

Edward B. Lee, MD, PhD, also describes how understanding Alzheimer disease requires the integration of multiple fields including genetics, pathology, epidemiology, pharmacology, and physiology.

The experimental drug successfully reduced levels of SIV, the nonhuman primate equivalent of HIV, in the brain.

Study results demonstrated that lecanemab provided sustained benefits over 36 months, such as improved biomarker profiles and slowed cognitive decline compared with placebo.

Tara Spires-Jones, DPhil, FMedSci, discusses how oligomeric tau clumps inside brain synapses, pointing to indirect evidence that it may be progressing through the brain by jumping between connections.

The co-founder, chief science officer, and chairman at Longeveron discusses the findings from the phase 2a trial CLEARMIND, as well as next steps to developing the therapy Lomecel-B.